Henry Ford Health System - Company Profile
Powered by 
All the data and insights you need on Henry Ford Health System in one report.
$295
- Save hours of research time and resources with
our up-to-date Henry Ford Health System Strategy Report
- Understand Henry Ford Health System position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Henry Ford Health System Clinical Trials
Determine Henry Ford Health System go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.
A sample of Henry Ford Health System Clinical Trials data
| Trial Title | Trial Identifier | Drug Name | Therapy Area | Indication | Trial Phase | Trial Status | Sponsor |
|---|---|---|---|---|---|---|---|
| Deserunt mollit sunt Lorem | GDCTWXYZ | Lorem | Lorem | Lorem | WXYZ | Planned | Pfizer Inc |
| Prospective Study of Stereotactic Radiology Using Diffusion-Weighted Abnormality Versus Chemotherapy for Recurrent/Progressive Glioblastoma After Second-Line Chemotherapy | GDCT0478451 | bevacizumab; carboplatin; etoposide; irinotecan; temozolomide | Oncology | Glioblastoma Multiforme (GBM); Gliosarcoma; Low-Grade Glioma; Recurrent Glioblastoma Multiforme (GBM) | Phase III | Completed | Henry Ford Health System |
| Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma. | GDCT0476841 | flucytosine; Oncolytic Virus to Activate Thymidine Kinase for Oncology; valganciclovir | Oncology | Anaplastic Astrocytoma; Astrocytoma; Brain Cancer; Brain Tumor; Glioblastoma Multiforme (GBM); Glioma; Malignant Glioma; Recurrent Glioblastoma Multiforme (GBM) | Phase I | Ongoing, recruiting | Henry Ford Health System |
| A Clinical Study to Assess the Changes in Left Ventricular Global Longitudinal Strain in Breast Cancer Subjects Receiving Anti-HER2 And/Or Adriamycin Therapy and Outcomes with Early Implementation of Cardio-protective Measures | GDCT0475499 | doxorubicin; undisclosed anti-HER2 therapy | Oncology | Breast Cancer | Phase II | Completed | Henry Ford Hospital;Henry Ford Health System |
Feature
GlobalData’s Clinical Trials database (CTDB) is a highly comprehensive source of Clinical Trials.
The database covers planned, ongoing, completed and terminated/suspended/withdrawn clinical trials.
Clinical Trials database provides intelligence on global clinical trials for all indications. The data is sourced from:
- 250+ clinical trial registries
- 200+ scientific and investor conferences, company pipelines, press releases, and SEC filings.
Benefit
The Clinical Trials database collects information on various parameters to provide a Clinical Trial overview as well as Clinical Trial details, Drug details, Patient details, Trial Results, Location(s)/Sponsor(s) and Contact Detail(s).
Access:
- Detailed trial information.
- Drug information.
- Patient information, including inclusion and exclusion criteria.
- Trial results, as reported in the public domain.
- Biomarkers used for patient stratification/selection & outcome measures.
- Enrolment parameters.
- Investigators involved in clinical trials.
- Trials sites and locations.
- Contact information.
Value
Competitive Activity – keep an eye on planned or ongoing trials, as well as the trials currently recruiting and who is sponsoring them.
Geographic Analysis - see where trials are being run.
Trend Analysis - view top sponsors, indications, phase, status and more with Trial Analytics.
Find information on trials contacts, as well as Site and Investigator information.
Get information on trial successes and failures.
Get intelligence on CROs engaged in clinical trials.
Use as a business development tool for CROs.
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer